A shortened IGF-1 analogue studied for growth-factor research, cellular growth pathways, muscle-tissue models, protein synthesis, tissue-repair signaling, anabolic response mechanisms, and localized IGF-1 receptor activity research.

Product Overview

Compound: IGF-DES / IGF-1 DES
Strength: 2 mg per vial
Injection type: Research protocol dependent
Frequency: Research protocol dependent

Reconstitution

Amount in vial: 2 mg
BAC water: 2 mL
Amount per unit: 10 mcg per unit

Research Dose

Protocol dependent.

Notes

IGF-DES, also known as IGF-1 DES, is described as a shortened analogue of insulin-like growth factor 1, lacking the first three amino acids of the native IGF-1 sequence. This structural modification is studied for its effect on IGF receptor interaction and reduced binding affinity to IGF-binding proteins in research models.

Research literature has examined IGF-1-related pathways in relation to cellular growth, muscle-cell differentiation, protein synthesis, glucose uptake, tissue-repair signaling, and anabolic regulation.

IGF-DES is often discussed in research contexts as having more localized and shorter-duration activity compared with longer-acting IGF-1 analogues, but no standard consumer dosing protocol should be assumed.

Most available evidence comes from laboratory, animal, and limited clinical-context research.

Use only within appropriate research or professional guidance frameworks.